- 米国企業
- Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc.SYRS
| 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 |
---|
Cash and cash equivalents | 59 | 32 | 50 | 41 | 174 | 92 | 167 |
---|
Marketable securities | 25 | 40 | 50 | 50 | - | 38 | 35 |
---|
Accounts receivable | 1 | - | - | - | 0 | - | - |
---|
Contract assets | - | - | - | - | 2 | 3 | 2 |
---|
Prepaid expenses and other current assets | 1 | 1 | 1 | 3 | 2 | 3 | 7 |
---|
Total current assets | 86 | 73 | 102 | 115 | 179 | 137 | 211 |
---|
Property and equipment, net | 5 | 4 | 4 | 15 | 14 | 13 | 11 |
---|
Marketable Securities, Noncurrent | - | - | - | - | - | 13 | - |
---|
Other long-term assets | 0 | 1 | 1 | 0 | 2 | 3 | 5 |
---|
Restricted cash | 0 | 0 | 0 | 3 | 3 | 3 | 3 |
---|
Operating Lease, Right-of-Use Asset | - | - | - | 16 | 15 | 14 | 13 |
---|
Right-of-use assets – financing leases | - | - | - | 1 | 1 | 0 | 0 |
---|
Total assets | 91 | 78 | 107 | 150 | 213 | 183 | 244 |
---|
Accounts payable | 2 | 2 | 3 | 6 | 4 | 4 | 6 |
---|
Accrued expenses | - | 10 | 14 | 11 | 11 | 16 | 18 |
---|
Deferred Revenue, Current | 1 | - | 2 | 6 | 12 | 10 | 4 |
---|
Finance Lease, Liability, Current | - | - | - | - | 0 | 0 | 0 |
---|
Operating Lease, Liability, Current | - | - | - | 1 | 1 | 2 | 2 |
---|
Total current liabilities | 10 | 12 | 20 | 24 | 29 | 32 | 31 |
---|
Deferred revenue, net of current portion | - | - | 8 | 23 | 10 | - | - |
---|
Finance Lease, Liability, Noncurrent | - | - | - | - | 0 | 0 | - |
---|
Operating Lease, Liability, Noncurrent | - | - | - | 24 | 25 | 23 | 21 |
---|
Warrant liabilities | - | - | - | - | 20 | 3 | 24 |
---|
Debt, net of debt discount, long term | - | - | - | - | 40 | 40 | 41 |
---|
Common Stock, Value, Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Additional paid-in capital | 182 | 221 | 296 | 372 | 468 | 549 | 686 |
---|
Accumulated other comprehensive loss | -0 | -0 | -0 | 0 | - | -0 | 0 |
---|
Accumulated deficit | -101 | -155 | -218 | -293 | -377 | -464 | -558 |
---|
Total stockholders' equity | 81 | 65 | 79 | 79 | 91 | 85 | 128 |
---|
Total liabilities and stockholders' equity | 91 | 78 | 107 | 150 | 213 | 183 | 244 |
---|